You are viewing: Saudi Arabia Oral Proteins & Peptides Market analysis

The Saudi Arabia Oral Proteins & Peptides Market was valued at $2.91 Million in 2025 and projected to reach to $5.57 Million by 2030, representing a compound annual growth rate of 13.9%. Saudi Arabia's oral proteins and peptides market is poised for significant expansion, driven by healthcare sector modernization initiatives and increasing prevalence of chronic diseases.

Saudi Arabia Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Saudi Arabia Oral Proteins & Peptides Market Trends and Insights

  • This represents a compound annual growth rate (CAGR) of 13.9%, reflecting increasing adoption of advanced pharmaceutical formulations across the Kingdom.
  • Saudi Arabia's healthcare sector modernization and rising prevalence of chronic diseases are driving demand for innovative oral delivery systems that enhance bioavailability and patient compliance. The market in Saudi Arabia is supported by substantial government healthcare investments and a growing focus on precision medicine.
  • Saudi Arabia's Vision 2030 initiative has accelerated pharmaceutical infrastructure development, creating favorable conditions for oral protein and peptide therapeutics.
  • Between 2025 and 2030, Saudi Arabia is expected to see heightened clinical adoption, particularly in diabetes management, gastrointestinal disorders, and immunological treatments.
  • The Kingdom's expanding middle class and improved healthcare accessibility further strengthen market penetration prospects. Saudi Arabia's regulatory environment continues to evolve, with the Saudi Food and Drug Authority (SFDA) streamlining approval pathways for innovative biologics.
  • This regulatory support, combined with increasing healthcare expenditure, positions Saudi Arabia as a key growth market within the GCC region for oral proteins and peptides..

Key Market Statistics

  • CAGR (2025-2030) 13.9% CAGR
  • Market Size, 2025 ~USD 2.91 Million
  • Forecast, 2030 ~USD 5.57 Million
  • Country Saudi Arabia

Saudi Arabia Oral Proteins & Peptides Market Overview

Market Valuation Growth :

Saudi Arabia's oral proteins and peptides market is valued at USD 2.91 million in 2025, with projections reaching USD 5.57 million by 2030, demonstrating strong market expansion potential in the Kingdom's pharmaceutical sector.

Robust CAGR Performance :

The market is growing at a CAGR of 13.9% through 2030, significantly outpacing many regional markets and reflecting increasing healthcare investment and pharmaceutical innovation adoption across Saudi Arabia.

Healthcare Modernization :

Saudi Arabia's Vision 2030 initiative is driving substantial modernization of the healthcare infrastructure, creating favorable conditions for advanced pharmaceutical formulations including oral proteins and peptides.

Chronic Disease Management :

Rising prevalence of chronic diseases in Saudi Arabia is accelerating demand for innovative therapeutic solutions, positioning oral proteins and peptides as critical treatment options for the growing patient population.

Saudi Arabia Oral Proteins & Peptides Market Dynamics

  • The Kingdom's commitment to diversifying its economy and enhancing healthcare capabilities under Vision 2030 is creating substantial opportunities for advanced pharmaceutical formulations.
  • Government investments in healthcare infrastructure and rising healthcare expenditure are facilitating adoption of innovative oral protein and peptide therapies. The market's 13.9% CAGR reflects growing awareness among healthcare professionals and patients regarding the benefits of oral protein and peptide-based treatments.
  • Increasing collaboration between international pharmaceutical companies and local healthcare providers, coupled with regulatory improvements, is expected to accelerate market penetration.
  • As Saudi Arabia continues to strengthen its pharmaceutical ecosystem, the oral proteins and peptides segment is anticipated to capture greater market share among therapeutic interventions..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Saudi Arabia's oral proteins & peptides market will nearly double from USD 2.91M (2025) to USD 5.57M (2030), driven by healthcare modernization and chronic disease prevalence.
    • Saudi Arabia's 13.9% CAGR outpaces many regional markets, supported by Vision 2030 healthcare infrastructure investments and SFDA regulatory streamlining.
    • Saudi Arabia's market growth is fueled by increasing adoption in diabetes, gastrointestinal, and immunological treatments, with enhanced patient compliance through oral delivery.
    • Saudi Arabia's expanding healthcare accessibility and rising middle-class purchasing power position the Kingdom as a strategic growth hub for oral protein therapeutics in the GCC.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Saudi Arabia Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical Companies : Manufacturers and distributors of oral proteins and peptides need Saudi Arabia-specific market data to develop localized commercialization strategies, assess market entry feasibility, and allocate resources effectively within the Kingdom.
    • Healthcare Investors : Investment firms and venture capitalists require detailed Saudi Arabia market insights to evaluate funding opportunities in biotech and pharmaceutical sectors, assess ROI potential, and identify high-growth segments within the Kingdom.
    • Government & Regulatory Bodies : Saudi Arabian health authorities and policy makers need market intelligence to inform healthcare policy decisions, regulatory frameworks, and resource allocation aligned with Vision 2030 healthcare objectives.
    • Healthcare Providers : Hospitals, clinics, and medical institutions in Saudi Arabia require market data to understand treatment trends, procurement planning, and integration of oral protein and peptide therapies into clinical protocols.
    • Market Research & Consulting Firms : Research organizations and consultants need Saudi Arabia-specific market cutouts to support client advisory services, competitive analysis, and strategic recommendations for stakeholders operating in the Kingdom's pharmaceutical sector.

    Key Companies in the Saudi Arabia Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Market-Specific Sizing Data : Access precise valuation figures for Saudi Arabia's oral proteins and peptides market with verified 2025 baseline (USD 2.91M) and 2030 forecasts (USD 5.57M), enabling accurate business planning and investment decisions.
    • Growth Trajectory Insights : Understand the 13.9% CAGR specific to Saudi Arabia's market dynamics, allowing stakeholders to benchmark performance against regional trends and identify competitive positioning opportunities within the Kingdom.
    • Vision 2030 Alignment : Leverage insights into how Saudi Arabia's healthcare modernization initiatives are directly impacting oral protein and peptide adoption, enabling strategic alignment with government priorities and policy developments.
    • Chronic Disease Context : Gain understanding of Saudi Arabia's specific chronic disease landscape driving demand for oral proteins and peptides, supporting targeted market entry strategies and product development initiatives.
    • Competitive Intelligence : Obtain Saudi Arabia-focused market analysis to identify gaps, competitive dynamics, and partnership opportunities within the Kingdom's pharmaceutical ecosystem for oral protein and peptide solutions.

    Frequently asked questions

    What is the current market size of oral proteins and peptides in Saudi Arabia?

    Saudi Arabia's oral proteins and peptides market was valued at USD 2.91 million in 2025 and is projected to reach USD 5.57 million by 2030.

    What is the expected growth rate for Saudi Arabia's oral proteins and peptides market?

    Saudi Arabia's market is expected to grow at a compound annual growth rate (CAGR) of 13.9% between 2025 and 2030.

    Which therapeutic areas are driving growth in Saudi Arabia's oral proteins market?

    Saudi Arabia's market growth is primarily driven by diabetes management, gastrointestinal disorders, and immunological treatments, where oral delivery systems improve patient compliance.

    How does Saudi Arabia's regulatory environment support oral protein development?

    Saudi Arabia's Food and Drug Authority (SFDA) has streamlined approval pathways for innovative biologics, facilitating faster market entry for oral protein and peptide therapeutics.

    What role does Vision 2030 play in Saudi Arabia's oral proteins market expansion?

    Saudi Arabia's Vision 2030 initiative has accelerated pharmaceutical infrastructure development and healthcare investments, creating favorable conditions for advanced oral delivery systems and precision medicine adoption.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status